KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Shares Issued (2016 - 2024)

Novavax has reported Shares Issued over the past 15 years, most recently at $256.4 million for Q2 2024.

  • Quarterly results put Shares Issued at $256.4 million for Q2 2024, up 313.66% from a year ago — trailing twelve months through Mar 2025 was $256.4 million (up 48.99% YoY), and the annual figure for FY2024 was $263.3 million, down 26.92%.
  • Shares Issued for Q2 2024 was $256.4 million at Novavax, up from $6.9 million in the prior quarter.
  • Over the last five years, Shares Issued for NVAX hit a ceiling of $538.0 million in Q3 2021 and a floor of $1.5 million in Q2 2020.
  • Median Shares Issued over the past 5 years was $103.2 million (2023), compared with a mean of $162.9 million.
  • Biggest five-year swings in Shares Issued: soared 19636.52% in 2020 and later plummeted 87.04% in 2021.
  • Novavax's Shares Issued stood at $428.6 million in 2020, then rose by 25.53% to $538.0 million in 2021, then crashed by 87.02% to $69.8 million in 2022, then surged by 47.82% to $103.2 million in 2023, then surged by 148.34% to $256.4 million in 2024.
  • The last three reported values for Shares Issued were $256.4 million (Q2 2024), $6.9 million (Q1 2024), and $103.2 million (Q4 2023) per Business Quant data.